 |
BioWorld-Insight-2010-10-04
Money Raised Year to Date
Q3: Post-ASCO Public Slump, But Venture Holds Steady
Despite the usual summer slowdown and some less-usual contributing factors, like a stock slump on the heels of the American Society of Clinical Oncology (ASCO) annual meeting in June, biotech fundraising continues to inch back from the brink.
Venture Capital And Other Investments In Private Biotechnology Companies: September 2010
No Abstract